Skip to main
OCGN

Ocugen, Inc. (OCGN) Stock Forecast & Price Target

Ocugen, Inc. (OCGN) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ocugen Inc. is focused on advancing innovative therapies, particularly in the realm of gene and cell treatments for retinal diseases, thereby addressing significant unmet medical needs. The company's ongoing clinical trials, particularly the promising phase I/II study of OCU400, indicate strong safety and efficacy, reinforcing the potential for substantial breakthroughs in inherited retinal diseases. Additionally, attractive collaboration opportunities and the prospect of mergers and acquisitions could further enhance Ocugen's growth potential and solidify its position in the biotechnology market.

Bears say

Ocugen Inc. is experiencing a negative outlook due to disappointing results related to its gene therapy for geographic atrophy (GA), with only 20.2% to 46% slowing of lesion growth reported in recent trials, which may not meet investor expectations. Furthermore, the company has cited challenges in securing necessary investment, attributing this issue to adverse market conditions and a stringent timeline for compliance with Nasdaq requirements. As a result, these factors contribute to concerns regarding Ocugen's financial health and future growth potential within its therapeutic pipeline.

Ocugen, Inc. (OCGN) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ocugen, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ocugen, Inc. (OCGN) Forecast

Analysts have given Ocugen, Inc. (OCGN) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Ocugen, Inc. (OCGN) has a Strong Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ocugen, Inc. (OCGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.